vs
Side-by-side financial comparison of AIRO Group Holdings, Inc. (AIRO) and Prelude Therapeutics Inc (PRLD). Click either name above to swap in a different company.
Prelude Therapeutics Inc is the larger business by last-quarter revenue ($6.5M vs $6.3M, roughly 1.0× AIRO Group Holdings, Inc.). AIRO Group Holdings, Inc. runs the higher net margin — -126.7% vs -303.5%, a 176.8% gap on every dollar of revenue.
Airo Aviation FZ-LLC was an Emirati aircraft manufacturer based in the Ras Al Khaimah Free Trade Zone. The company specialized in the manufacture of ultralight aircraft in the form of ready-to-fly aircraft for the European Fédération Aéronautique Internationale microlight category.
AIRO vs PRLD — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.3M | $6.5M |
| Net Profit | $-8.0M | $-19.7M |
| Gross Margin | 44.4% | — |
| Operating Margin | -190.7% | -314.1% |
| Net Margin | -126.7% | -303.5% |
| Revenue YoY | — | 116.7% |
| Net Profit YoY | — | 38.9% |
| EPS (diluted) | $-0.28 | $-0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $6.3M | $6.5M | ||
| Q2 25 | $24.6M | — | ||
| Q3 24 | — | $3.0M |
| Q3 25 | $-8.0M | $-19.7M | ||
| Q2 25 | $5.9M | — | ||
| Q3 24 | — | $-32.3M |
| Q3 25 | 44.4% | — | ||
| Q2 25 | 61.2% | — | ||
| Q3 24 | — | — |
| Q3 25 | -190.7% | -314.1% | ||
| Q2 25 | -80.2% | — | ||
| Q3 24 | — | -1145.9% |
| Q3 25 | -126.7% | -303.5% | ||
| Q2 25 | 23.9% | — | ||
| Q3 24 | — | -1075.7% |
| Q3 25 | $-0.28 | $-0.26 | ||
| Q2 25 | $0.30 | — | ||
| Q3 24 | — | $-0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $55.0M |
| Total DebtLower is stronger | $5.1M | — |
| Stockholders' EquityBook value | $739.5M | $58.5M |
| Total Assets | $774.6M | $94.8M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $55.0M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | $153.6M |
| Q3 25 | $5.1M | — | ||
| Q2 25 | $8.9M | — | ||
| Q3 24 | — | — |
| Q3 25 | $739.5M | $58.5M | ||
| Q2 25 | $679.6M | — | ||
| Q3 24 | — | $156.4M |
| Q3 25 | $774.6M | $94.8M | ||
| Q2 25 | $747.8M | — | ||
| Q3 24 | — | $197.2M |
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q3 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.8M | $-19.1M |
| Free Cash FlowOCF − Capex | $-6.7M | — |
| FCF MarginFCF / Revenue | -106.7% | — |
| Capex IntensityCapex / Revenue | 15.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-5.8M | $-19.1M | ||
| Q2 25 | $-30.8M | — | ||
| Q3 24 | — | $-27.3M |
| Q3 25 | $-6.7M | — | ||
| Q2 25 | $-31.8M | — | ||
| Q3 24 | — | $-27.4M |
| Q3 25 | -106.7% | — | ||
| Q2 25 | -129.6% | — | ||
| Q3 24 | — | -912.0% |
| Q3 25 | 15.0% | 0.0% | ||
| Q2 25 | 4.3% | — | ||
| Q3 24 | — | 2.1% |
| Q3 25 | — | — | ||
| Q2 25 | -5.24× | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIRO
| Transferred At Point In Time | $4.5M | 71% |
| Transferred Over Time | $1.8M | 29% |
PRLD
Segment breakdown not available.
